Cite
HARVARD Citation
Long, G. et al. (2019). Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Annals of oncology. p. 1848. [Online].